[Comment] Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?

April, 04, 2024 | Select Oncology Journal Articles

Adrenocortical carcinoma is a rare cancer with a dismal prognosis, which affects 1–2 people per million annually, worldwide.1 Because of the small number of patients within single centres and the scarcity of preclinical models until recently,2 advancements in treatment options have been limited. Mitotane, a cell-specific adrenolytic, has been the mainstay of treatment, together with etoposide, doxorubicin, and cisplatin chemotherapy.3 Early studies with tyrosine kinase inhibitors (TKIs) have not shown a strong signal of response in patients with adrenocortical carcinoma as monotherapy.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy